Pulmonary host defenses and alcohol.

Front Biosci

Department of Medicine, Section of Pulmonary and Critical Care Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.

Published: May 2002

Alcohol abuse is a major risk factor for the development of many infectious diseases, particularly pulmonary infections. Bacterial pneumonia and other lung infections in alcohol-abusing patients are usually severe and associated with a high morbidity and mortality. Normal host defense mechanisms in the respiratory tract consist of both innate and acquired immunity which operate effectively in preventing the invasion of infectious pathogens. Numerous in vivo and in vitro studies have shown that alcohol is an immunosuppressive agent that compromises the function of various components of the immune defense system. In recent years, human immunodeficiency virus infection has become epidemic, especially in individuals who abuse alcohol and other substances. Treatment of pulmonary infections in these immunocompromised hosts has continued to be a major challenge in our health care system. Immunotherapy to improve or enhance pulmonary host defense function in conjunction with aggressive antimicrobial regimens may provide a new approach in the management of infections in these patients.

Download full-text PDF

Source
http://dx.doi.org/10.2741/A842DOI Listing

Publication Analysis

Top Keywords

pulmonary host
8
pulmonary infections
8
host defense
8
pulmonary
4
host defenses
4
alcohol
4
defenses alcohol
4
alcohol alcohol
4
alcohol abuse
4
abuse major
4

Similar Publications

Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function.

PLoS One

January 2025

Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

T-cell response plays an important role in SARS-CoV-2 immunogenicity. For people living with HIV (PWH) and solid organ transplant (SOT) recipients there is limited evidence on the reliability of commercially available T-cell tests. We assessed 173 blood samples from 81 participants (62 samples from 35 PWH; 111 samples from 46 SOT recipients [lung and kidney]) with two commercial SARS-CoV-2 Interferon-γ (IFN-γ) release assays (IGRA; SARS-CoV-2 IGRA by Euroimmun, and IGRA SARS-CoV-2 by Roche).

View Article and Find Full Text PDF

Background: The mycobiome in the tumor microenvironment of non-smokers with early-stage lung adenocarcinoma (ES-LUAD) has been minimally investigated.

Methods: In this study, we conducted ultra-deep metagenomic and transcriptomic sequencing on 128 samples collected from 46 nonsmoking ES-LUAD patients and 41 healthy controls (HC), aiming to characterize the tumor-resident mycobiome and its interactions with the host.

Results: The results revealed that ES-LUAD patients exhibited fungal dysbiosis characterized by reduced species diversity and significant imbalances in specific fungal abundances.

View Article and Find Full Text PDF

Unlabelled: Members of the RNA virus order infect hosts ranging from marine invertebrates to terrestrial mammals. As such, understanding the determinants of host range in this group of viruses, as well as their patterns of emergence and disease potential, is of clear importance. The are a recently documented family within the .

View Article and Find Full Text PDF

Background: Equine herpesvirus type 1 (EHV1) is a ubiquitous viral pathogen infecting the equine population worldwide. EHV1 infection causes respiratory illness, abortion, neonatal foal mortality, and myeloencephalopathy. The currently available modified live EHV1 vaccines have safety and efficacy limitations.

View Article and Find Full Text PDF

Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy.

Vaccines (Basel)

December 2024

Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China.

The persistent threat of COVID-19, particularly with the emergence of new variants, underscores the urgency for innovative therapeutic strategies beyond conventional antiviral treatments. Current immunotherapies, including IL-6/IL-6R monoclonal antibodies and JAK inhibitors, exhibit suboptimal efficacy, necessitating alternative approaches. Our review delves into the significance of NAD+ metabolism in COVID-19 pathology, marked by decreased NAD+ levels and upregulated NAD+-consuming enzymes such as CD38 and poly (ADP-ribose) polymerases (PARPs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!